(TWST) Twist Bioscience - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US90184D1000
Synthetic DNA, Gene Fragments, Oligo Pools, NGS Tools, Antibody Libraries
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 68.6% |
| Value at Risk 5%th | 106% |
| Relative Tail Risk | -5.92% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.31 |
| Alpha | -55.64 |
| CAGR/Max DD | 0.06 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.437 |
| Beta | 1.767 |
| Beta Downside | 1.294 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.82% |
| Mean DD | 29.16% |
| Median DD | 28.58% |
Description: TWST Twist Bioscience November 12, 2025
Twist Bioscience Corp. (NASDAQ:TWST) manufactures synthetic DNA-based products, supplying gene fragments, oligo pools, and custom immunoglobulin G proteins for applications ranging from therapeutics and diagnostics to data storage and agricultural biotech. Its portfolio also includes next-generation sequencing (NGS) kits, methylation detection assays, and a suite of synthetic viral controls (e.g., SARS-CoV-2, monkeypox) that support assay development and research panels for respiratory pathogens.
Key recent metrics: FY 2023 revenue reached approximately $1.0 billion, up ~35 % YoY, driven by strong demand for high-throughput DNA synthesis in CRISPR-based drug discovery and expanding NGS diagnostic markets. The global synthetic DNA market is projected to grow at a CAGR of 15 % through 2030, with biotech R&D spend and the rise of DNA-based data storage acting as primary tailwinds. Twist’s strategic alliance with bitBiome enhances its capability to deliver large-scale, high-accuracy DNA libraries for antibody engineering, a segment that has seen a 20 % increase in funding across the pharma sector in the past year.
For a deeper, data-driven assessment of Twist’s valuation and competitive positioning, you may find ValueRay’s analytical toolkit worth exploring.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-77.5m TTM) > 0 and > 6% of Revenue (6% = 22.6m TTM) |
| FCFTA -0.12 (>2.0%) and ΔFCFTA -0.52pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 64.15% (prev 88.11%; Δ -23.97pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.07 (>3.0%) and CFO -47.6m > Net Income -77.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.64 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (60.4m) change vs 12m ago 4.15% (target <= -2.0% for YES) |
| Gross Margin 50.72% (prev 42.61%; Δ 8.11pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 59.95% (prev 50.95%; Δ 9.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -298.8 (EBITDA TTM -57.7m / Interest Expense TTM 167.0k) >= 6 (WARN >= 3) |
Altman Z'' -12.97
| (A) 0.38 = (Total Current Assets 333.0m - Total Current Liabilities 91.4m) / Total Assets 641.9m |
| (B) -2.06 = Retained Earnings (Balance) -1.32b / Total Assets 641.9m |
| warn (B) unusual magnitude: -2.06 — check mapping/units |
| (C) -0.08 = EBIT TTM -49.9m / Avg Total Assets 628.1m |
| (D) -7.82 = Book Value of Equity -1.32b / Total Liabilities 168.9m |
| Total Rating: -12.97 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 35.70
| 1. Piotroski 2.50pt |
| 2. FCF Yield -5.26% |
| 3. FCF Margin -20.08% |
| 4. Debt/Equity 0.16 |
| 5. Debt/Ebitda 1.86 |
| 6. ROIC - WACC (= -23.04)% |
| 7. RoE -16.78% |
| 8. Rev. Trend 98.69% |
| 9. EPS Trend 63.60% |
What is the price of TWST shares?
As of December 01, 2025, the stock is trading at USD 32.01 with a total of 497,090 shares traded.
Over the past week, the price has changed by +9.14%, over one month by -2.68%, over three months by +21.99% and over the past year by -36.36%.
Over the past week, the price has changed by +9.14%, over one month by -2.68%, over three months by +21.99% and over the past year by -36.36%.
Is TWST a buy, sell or hold?
Twist Bioscience has received a consensus analysts rating of 4.17.
Therefore, it is recommended to buy TWST.
- Strong Buy: 6
- Buy: 3
- Hold: 2
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the TWST price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 35.6 | 11.3% |
| Analysts Target Price | 35.6 | 11.3% |
| ValueRay Target Price | 32.4 | 1.2% |
TWST Fundamental Data Overview November 22, 2025
Market Cap USD = 1.59b (1.59b USD * 1.0 USD.USD)
P/S = 4.2333
P/B = 3.2904
Beta = 2.244
Revenue TTM = 376.6m USD
EBIT TTM = -49.9m USD
EBITDA TTM = -57.7m USD
Long Term Debt = 75.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.8m USD (from shortTermDebt, last quarter)
Debt = 75.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -107.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.44b USD (1.59b + Debt 75.6m - CCE 232.4m)
Interest Coverage Ratio = -298.8 (Ebit TTM -49.9m / Interest Expense TTM 167.0k)
FCF Yield = -5.26% (FCF TTM -75.6m / Enterprise Value 1.44b)
FCF Margin = -20.08% (FCF TTM -75.6m / Revenue TTM 376.6m)
Net Margin = -20.58% (Net Income TTM -77.5m / Revenue TTM 376.6m)
Gross Margin = 50.72% ((Revenue TTM 376.6m - Cost of Revenue TTM 185.6m) / Revenue TTM)
Gross Margin QoQ = 51.35% (prev 53.40%)
Tobins Q-Ratio = 2.24 (Enterprise Value 1.44b / Total Assets 641.9m)
Interest Expense / Debt = 0.19% (Interest Expense 143.0k / Debt 75.6m)
Taxrate = -2.43% (negative due to tax credits) (639.0k / -26.3m)
NOPAT = -51.1m (EBIT -49.9m * (1 - -2.43%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 3.64 (Total Current Assets 333.0m / Total Current Liabilities 91.4m)
Debt / Equity = 0.16 (Debt 75.6m / totalStockholderEquity, last quarter 473.0m)
Debt / EBITDA = 1.86 (negative EBITDA) (Net Debt -107.5m / EBITDA -57.7m)
Debt / FCF = 1.42 (negative FCF - burning cash) (Net Debt -107.5m / FCF TTM -75.6m)
Total Stockholder Equity = 461.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.08% (Net Income -77.5m / Total Assets 641.9m)
RoE = -16.78% (Net Income TTM -77.5m / Total Stockholder Equity 461.8m)
RoCE = -9.29% (EBIT -49.9m / Capital Employed (Equity 461.8m + L.T.Debt 75.6m))
RoIC = -11.07% (negative operating profit) (NOPAT -51.1m / Invested Capital 461.8m)
WACC = 11.97% (E(1.59b)/V(1.67b) * Re(12.53%) + D(75.6m)/V(1.67b) * Rd(0.19%) * (1-Tc(-0.02)))
Discount Rate = 12.53% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.51%
Fair Price DCF = unknown (Cash Flow -75.6m)
EPS Correlation: 63.60 | EPS CAGR: 15.57% | SUE: 0.18 | # QB: 0
Revenue Correlation: 98.69 | Revenue CAGR: 25.68% | SUE: 1.00 | # QB: 1
EPS next Quarter (2025-12-31): EPS=-0.52 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-09-30): EPS=-1.76 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+16.8% | Growth Revenue=+14.4%
EPS next Year (2027-09-30): EPS=-1.05 | Chg30d=-0.169 | Revisions Net=-2 | Growth EPS=+29.4% | Growth Revenue=+15.4%
P/S = 4.2333
P/B = 3.2904
Beta = 2.244
Revenue TTM = 376.6m USD
EBIT TTM = -49.9m USD
EBITDA TTM = -57.7m USD
Long Term Debt = 75.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.8m USD (from shortTermDebt, last quarter)
Debt = 75.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -107.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.44b USD (1.59b + Debt 75.6m - CCE 232.4m)
Interest Coverage Ratio = -298.8 (Ebit TTM -49.9m / Interest Expense TTM 167.0k)
FCF Yield = -5.26% (FCF TTM -75.6m / Enterprise Value 1.44b)
FCF Margin = -20.08% (FCF TTM -75.6m / Revenue TTM 376.6m)
Net Margin = -20.58% (Net Income TTM -77.5m / Revenue TTM 376.6m)
Gross Margin = 50.72% ((Revenue TTM 376.6m - Cost of Revenue TTM 185.6m) / Revenue TTM)
Gross Margin QoQ = 51.35% (prev 53.40%)
Tobins Q-Ratio = 2.24 (Enterprise Value 1.44b / Total Assets 641.9m)
Interest Expense / Debt = 0.19% (Interest Expense 143.0k / Debt 75.6m)
Taxrate = -2.43% (negative due to tax credits) (639.0k / -26.3m)
NOPAT = -51.1m (EBIT -49.9m * (1 - -2.43%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 3.64 (Total Current Assets 333.0m / Total Current Liabilities 91.4m)
Debt / Equity = 0.16 (Debt 75.6m / totalStockholderEquity, last quarter 473.0m)
Debt / EBITDA = 1.86 (negative EBITDA) (Net Debt -107.5m / EBITDA -57.7m)
Debt / FCF = 1.42 (negative FCF - burning cash) (Net Debt -107.5m / FCF TTM -75.6m)
Total Stockholder Equity = 461.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.08% (Net Income -77.5m / Total Assets 641.9m)
RoE = -16.78% (Net Income TTM -77.5m / Total Stockholder Equity 461.8m)
RoCE = -9.29% (EBIT -49.9m / Capital Employed (Equity 461.8m + L.T.Debt 75.6m))
RoIC = -11.07% (negative operating profit) (NOPAT -51.1m / Invested Capital 461.8m)
WACC = 11.97% (E(1.59b)/V(1.67b) * Re(12.53%) + D(75.6m)/V(1.67b) * Rd(0.19%) * (1-Tc(-0.02)))
Discount Rate = 12.53% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.51%
Fair Price DCF = unknown (Cash Flow -75.6m)
EPS Correlation: 63.60 | EPS CAGR: 15.57% | SUE: 0.18 | # QB: 0
Revenue Correlation: 98.69 | Revenue CAGR: 25.68% | SUE: 1.00 | # QB: 1
EPS next Quarter (2025-12-31): EPS=-0.52 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-09-30): EPS=-1.76 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+16.8% | Growth Revenue=+14.4%
EPS next Year (2027-09-30): EPS=-1.05 | Chg30d=-0.169 | Revisions Net=-2 | Growth EPS=+29.4% | Growth Revenue=+15.4%
Additional Sources for TWST Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle